Programmed Cell Death Protein 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Immunotherapy: A Promising Breakthrough in Cancer Therapeutics

The advent of immune checkpoint inhibitors has revolutionized cancer therapy by leveraging the body's immune system to combat malignancies effectively. Among these groundbreaking agents, programmed cell death protein 1 (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors have emerged as...

Descripción completa

Detalles Bibliográficos
Autores principales: Abaza, Abdelrahman, Sid Idris, Faten, Anis Shaikh, Humna, Vahora, Ilma, Moparthi, Kiran Prasad, Al Rushaidi, Majdah T, Muddam, Meghana Reddy, Obajeun, Omobolanle A, Jaramillo, Arturo P, Khan, Safeera
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Pathology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10475160/
https://www.ncbi.nlm.nih.gov/pubmed/37667784
http://dx.doi.org/10.7759/cureus.44582

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10475160/
https://www.ncbi.nlm.nih.gov/pubmed/37667784
http://dx.doi.org/10.7759/cureus.44582

Ejemplares similares